Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.
Neeraj Y SainiDavid M SwobodaUri GreenbaumJunsheng MaRomil D PatelKartik DevashishKaberi DasMark R TannerPaolo StratiRanjit NairLuis FayadSairah A AhmedHun Ju LeeSwaminathan P IyerRaphael E SteinerNitin JainLoretta NastoupilSanam LoghaviGuilin TangRoland L BassettPreetesh JainMichael L WangJason R WestinMichael R GreenDavid A SallmanEric PadronMarco L DavilaFrederick L LockeRichard E ChamplinGuillermo Garcia-ManeroElizabeth J ShpallPartow KebriaeiChristopher R FlowersMichael D JainFeng WangAndrew P FutrealNancy GillisSattva S NeelapuKoichi TakahashiPublished in: Blood cancer discovery (2022)
Our study reveals that CH mutations, especially those associated with inflammation (DNMT3A, TET2, and ASXL1), are associated with severe-grade neurotoxicities in lymphoma patients receiving anti-CD19 CAR T-cell therapy. Further studies to investigate the mechanisms and interventions to improve toxicities in the context of CH are warranted. See related content by Uslu and June, p. 382. This article is highlighted in the In This Issue feature, p. 369.